These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22083792)

  • 1. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical Approaches to Forced Degradation Studies of Vaccines.
    Hasija M; Aboutorabian S; Rahman N; Ausar SF
    Methods Mol Biol; 2016; 1403():853-66. PubMed ID: 27076171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.
    Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
    Eur J Pharm Biopharm; 2013 Oct; 85(2):240-52. PubMed ID: 23727369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of forced degradation behavior of eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method.
    Jocić B; Zecević M; Zivanović L; Protić A; Jadranin M; Vajs V
    J Pharm Biomed Anal; 2009 Nov; 50(4):622-9. PubMed ID: 19250786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.
    Sengupta P; Chatterjee B; Tekade RK
    Int J Pharm; 2018 May; 543(1-2):328-344. PubMed ID: 29635054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated stability studies of abatacept formulations: comparison of freeze-thawing- and agitation-induced stresses.
    Cordes AA; Carpenter JF; Randolph TW
    J Pharm Sci; 2012 Jul; 101(7):2307-15. PubMed ID: 22488299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced degradation of recombinant monoclonal antibodies: A practical guide.
    Nowak C; K Cheung J; M Dellatore S; Katiyar A; Bhat R; Sun J; Ponniah G; Neill A; Mason B; Beck A; Liu H
    MAbs; 2017; 9(8):1217-1230. PubMed ID: 28853987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.
    Cleland JL; Powell MF; Shire SJ
    Crit Rev Ther Drug Carrier Syst; 1993; 10(4):307-77. PubMed ID: 8124728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical lessons learned from selected therapeutic protein drug comparability studies.
    Federici M; Lubiniecki A; Manikwar P; Volkin DB
    Biologicals; 2013 May; 41(3):131-47. PubMed ID: 23146362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation.
    Arthur KK; Dinh N; Gabrielson JP
    J Pharm Sci; 2015 Apr; 104(4):1548-54. PubMed ID: 25561411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances.
    Bao Y; Mo X; Xu X; He Y; Xu X; An H
    J Pharm Biomed Anal; 2008 Nov; 48(3):664-71. PubMed ID: 18678459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
    Zelesky T; Baertschi SW; Foti C; Allain LR; Hostyn S; Franca JR; Li Y; Marden S; Mohan S; Ultramari M; Huang Z; Adams N; Campbell JM; Jansen PJ; Kotoni D; Laue C
    J Pharm Sci; 2023 Dec; 112(12):2948-2964. PubMed ID: 37690775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forced degradation studies: current trends and future perspectives for protein-based therapeutics.
    Chan CP
    Expert Rev Proteomics; 2016 Jul; 13(7):651-8. PubMed ID: 27285431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
    Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
    J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Degradation Chemistry of Farglitazar and Elucidation of the Oxidative Degradation Mechanisms.
    Reynolds DW; Campbell JM; Johnson BS; Joshi BK; Facchine KL; Long S; O'Connell TM; Paulus IV; Sides SL; Kraft ES; Wolters AM
    J Pharm Sci; 2017 Apr; 106(4):982-993. PubMed ID: 27988163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stressed Stability Techniques for Adjuvant Formulations.
    Hasija M; Sheung A; Rahman N; Ausar SF
    Methods Mol Biol; 2017; 1494():227-238. PubMed ID: 27718197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A validated stability indicating ion-pair RP-LC method for zoledronic acid.
    Rao BM; Srinivasu MK; Rani ChP; kumar SS; Kumar PR; Chandrasekhar KB; Veerender M
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):781-90. PubMed ID: 15922532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stability factor: importance in formulation development.
    Krishnamurthy R; Manning MC
    Curr Pharm Biotechnol; 2002 Dec; 3(4):361-71. PubMed ID: 12463418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.